NCT02260037View on ClinicalTrials.gov

Dose Tolerance Study in Healthy Male Volunteers After Intranasal Application of Epinastine Nasal

PHASE1CompletedINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

August 31, 2001

Primary Completion Date

September 30, 2001

Conditions
Healthy
Interventions
DRUG

Epinastine nasal

DRUG

Placebo

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY